AbbVie sponsored the study. Dr. Poordad has received research support and acted as a consultant to the company. He also disclosed receiving grants or research support or acting as an adviser or speaker for Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, in addition to others.
Conference Coverage
All-oral, triple-acting HCV regimen cures more than 90% of cirrhotic cases
More Liver Disease News
- Prognostic tool identifies alcohol relapse risk after liver transplant
- Liver-resident T cells provide early protection against Listeria infection
- Nano drug delivery could overcome toxicity in HCC to enable safer, more effective therapy
- Neutrophils may offer therapeutic target for Wilson’s disease
- MASLD/MASH and Weight Loss
- Gastroenterology Data Trends 2023
- AGA CPU focuses on noninvasive tests in patients with NAFLD
- Hepatic presentations of celiac disease
Question 1 of 5